Category: Uncategorized

IgA Realted Diseases

The renal group

IgA nephropathy (primary)
The commonest primary glomerulonephritis worldwide, with a marked predilection for East Asian and, to a lesser extent, European populations, and a peak in the second and third decades. The clinical signature is synpharyngitic visible haematuria — gross haematuria within a day or two of a mucosal (usually upper respiratory) infection — which contrasts usefully with the one-to-two-week latency of post-streptococcal GN. The rest present with asymptomatic microscopic haematuria and variable proteinuria picked up on screening. Pathogenesis is the four-hit model: circulating galactose-deficient IgA1 (hit one), glycan-specific autoantibodies against it (hit two, often IgG), immune-complex formation (hit three), and mesangial deposition with alternative- and lectin-pathway complement activation (hit four). Light microscopy shows mesangial hypercellularity and matrix expansion, with variable endocapillary proliferation, crescents and segmental sclerosis; the Oxford MEST-C score formalises the prognostically relevant lesions. IF gives dominant/codominant mesangial IgA with C3, frequently IgG/IgM, and — the point that keeps recurring — no C1q. EM confirms paramesangial dense deposits. Course is heterogeneous, with a substantial minority reaching ESRD over two decades.

IgA vasculitis nephritis (Henoch–Schönlein)
Best understood as the systemic expression of the same galactose-deficient-IgA1 biology, so the renal lesion is histologically and immunopathologically indistinguishable from primary IgAN — the biopsy alone cannot separate them. What separates them is the clinical tetrad: palpable purpura over the buttocks and lower limbs, arthralgia/arthritis, abdominal pain (with the risk of intussusception and GI haemorrhage), and nephritis. It is the commonest vasculitis of childhood, tends to be self-limiting in children, and behaves worse renally in adults. Crescents dominate the prognosis, and the paediatric lesion is graded by the ISKDC crescent-based scheme rather than MEST-C. Skin DIF shows perivascular IgA, tying it to the cutaneous vasculitis below.

IgA-dominant infection-related GN
The classic trap on this panel: IgA dominance or codominance in a GN that is emphatically not IgAN. It is typically staphylococcal (MRSA or MSSA), disproportionately in older and diabetic patients, and — unlike post-streptococcal disease — the infection is often ongoing rather than resolved (deep-seated soft-tissue, skin, endocarditis or visceral). Histology is an acute diffuse endocapillary and exudative proliferative GN with neutrophils, sometimes crescents, and subepithelial “humps” on EM. IF shows IgA with characteristically strong C3. The disambiguators from IgAN are therefore threefold: the clinical setting (active infection, diabetic/elderly), the exudative proliferative morphology with humps, and the disproportionate C3. Prognosis is guarded, especially in diabetics.

Lupus nephritis (as mimic)
Included only because its “full-house” IF (IgG, IgA, IgM, C3 and C1q) contains IgA, so isolated attention to the IgA channel is misleading. C1q positivity is the swing marker that pulls the case towards lupus and away from IgAN. Corroborating features — tubuloreticular inclusions on EM, wire-loop deposits, extraglomerular deposits along the TBM and vessels — and the ISN/RPS class then take over. IgA here is a passenger, never dominant in the IgAN sense.

Secondary (“hepatic”) mesangial IgA
Reduced hepatic clearance of IgA and IgA-containing immune complexes in chronic liver disease — most consistently alcohol-related cirrhosis with portal hypertension — produces mesangial IgA deposition that is usually clinically silent and lacks the proliferative lesion of primary IgAN. The same incidental deposition is described, less consistently, in coeliac disease, IBD, HIV, dermatitis herpetiformis and the seronegative spondyloarthropathies. The practical error to avoid is reading incidental mesangial IgA as primary IgAN without the clinicopathological context.

The cutaneous group

Dermatitis herpetiformis
The cutaneous face of coeliac disease: intensely pruritic grouped papulovesicles over extensor surfaces — elbows, knees, buttocks, scalp — usually excoriated by the time they present. Histology is a subepidermal blister with neutrophilic microabscesses at the tips of the dermal papillae. DIF on perilesional or clinically normal skin shows granular IgA at the papillary tips (with variable BMZ granularity). The autoantigen is epidermal transglutaminase (TG3), the cousin of the tissue transglutaminase (TG2) targeted in gut coeliac disease, and the HLA association is DQ2/DQ8. It responds to a gluten-free diet and to dapsone. The clinically useful cross-link for your GI work: a confirmed DH diagnosis is effectively a coeliac diagnosis, and these patients carry the associated enteropathy and lymphoma risk even when gut symptoms are absent.

Linear IgA bullous dermatosis
A subepidermal blistering disease defined by homogeneous linear IgA along the basement membrane zone — the pattern, not the immunoglobulin class alone, is what distinguishes it from DH. It has an adult idiopathic form and a childhood form (chronic bullous disease of childhood) with the characteristic annular “cluster of jewels”/string-of-pearls arrangement of peripheral blisters. The drug-induced variant is classically vancomycin-associated (also captopril, NSAIDs and others). The target antigens are cleavage products of BP180/collagen XVII (LAD-1, LABD97). Routine histology — a subepidermal blister with neutrophils — overlaps with both DH and bullous pemphigoid, so DIF is the arbiter: linear rather than granular, IgA rather than IgG.

IgA pemphigus
Intraepidermal acantholysis with intercellular (“chicken-wire”) IgA on DIF — the same cell-surface pattern as classical pemphigus but with IgA replacing IgG, and generally a more pustular, less erosive clinical picture (flaccid pustules, sometimes sunflower-like annular lesions with central crust). Two subtypes: the subcorneal pustular dermatosis (SPD) type, with subcorneal pustules and desmocollin 1 as the target antigen, and the intraepidermal neutrophilic (IEN) type, with pustules deeper in the epidermis and a less consistently defined antigen. The contrast to hold in mind is that pemphigus vulgaris and foliaceus are IgG-mediated intercellular disease; IgA pemphigus is their IgA counterpart, generally milder and steroid/dapsone-responsive.

Cutaneous IgA vasculitis
A leukocytoclastic vasculitis of superficial dermal small vessels with perivascular IgA on DIF — the skin lesion (palpable purpura) that, when accompanied by the systemic tetrad, marks IgA vasculitis, and which links directly back to the renal lesion above. The presence of IgA in the vessel walls is what elevates a non-specific leukocytoclastic vasculitis into this specific, systemically significant category.

The immunodeficiency

Selective IgA deficiency
The commonest primary immunodeficiency in populations of European descent (roughly 1 in 300–700), defined by very low or absent serum IgA with preserved IgG and IgM. Most are asymptomatic; a minority have recurrent sinopulmonary and GI infection, atopy, or autoimmune disease. In tissue it shows as reduced or absent IgA plasma cells in the lamina propria, and it associates with nodular lymphoid hyperplasia and giardiasis. Two practical consequences deserve flagging on any sheet: it invalidates IgA-based coeliac serology (the IgA-tTG will be falsely negative, so total IgA must be checked and IgG-based tests used instead), and it carries a risk of anaphylactic transfusion reactions to IgA-containing blood products in patients who have formed anti-IgA antibodies.

CDX2 Immunohistochemistry

CDX2 Immunohistochemistry

CDX2 is a homeobox transcription factor involved in intestinal epithelial development and differentiation. In diagnostic IHC, it is used as a sensitive and relatively specific marker of intestinal differentiation, most commonly applied to identify adenocarcinomas of gastrointestinal origin — particularly colorectal adenocarcinoma. Staining is nuclear.

Utility and limitations

CDX2 positivity is seen in the great majority of colorectal adenocarcinomas, making it a workhorse marker when confirming intestinal-type differentiation in a metastatic adenocarcinoma of unknown primary. However, it is not colorectal-specific: CDX2 is also expressed in a range of other tumours with intestinal or intestinal-type differentiation, including gastric adenocarcinoma (particularly intestinal-type), a subset of pancreaticobiliary adenocarcinomas, mucinous ovarian tumours, and some urothelial carcinomas with glandular/intestinal metaplasia.

Loss of CDX2 expression has also been reported as a marker of aggressive behaviour and worse prognosis in a subset of colorectal cancers, and can occur in poorly differentiated or dedifferentiated tumours — so a negative result doesn’t exclude colorectal origin, especially in high-grade lesions.

Panel context

Because of these overlaps, CDX2 is best used as part of a panel rather than as a standalone site-of-origin marker:

  • CK7/CK20: classic colorectal profile is CK20+/CK7−, though this pattern has well-known exceptions.
  • SATB2: increasingly regarded as more specific for colorectal origin than CDX2, since SATB2 is less frequently positive in upper GI and pancreaticobiliary tumours.
  • Villin: broadly supports intestinal/brush-border differentiation but shows similarly broad expression across GI sites.

Combining CDX2 with SATB2, CK7, CK20, and villin gives a more reliable picture of the site of origin than any single marker, particularly when trying to distinguish colorectal from upper GI or pancreaticobiliary adenocarcinoma in a metastatic workup.

BSEP (Bile Salt Export Pump) Immunohistochemistry

Bile Salt Export Pump (BSEP) is an ATP-binding cassette transporter protein (encoded by ABCB11) that functions as the major canalicular bile salt transporter in hepatocytes. In diagnostic pathology, BSEP IHC is used primarily as a canalicular marker for hepatocellular carcinoma and in the diagnosis of bile salt export pump deficiency in progressive familial intrahepatic cholestasis type 2 (PFIC2).

Hepatocellular carcinoma

BSEP shows a canalicular (“chicken-wire”) staining pattern in tumour cells, reflecting its normal physiological role as a bile salt transporter. This pattern confirms hepatocellular differentiation and helps distinguish HCC from metastatic adenocarcinoma or cholangiocarcinoma, neither of which forms canaliculi and therefore won’t show this staining pattern.

BSEP functions conceptually alongside other canalicular markers such as polyclonal CEA and CD10, and is generally considered more sensitive and specific than pCEA in some series.

Loss or reduction of BSEP staining has also been reported in poorly differentiated HCC and in some cholestatic hepatocellular lesions, so absent staining isn’t specific on its own — pattern interpretation in context matters.

Progressive Familial Intrahepatic Cholestasis Type 2

PFIC2 results from biallelic ABCB11 mutations. Liver biopsy IHC typically shows absent or markedly reduced canalicular BSEP staining, supporting the diagnosis alongside clinical/biochemical features (low-GGT cholestasis, elevated bile acids) and molecular confirmation.

A useful nuance: some ABCB11 missense mutations produce a mistrafficked but partially functional protein, which can show weak/patchy canalicular staining or an intracellular rather than purely canalicular pattern — so BSEP IHC is supportive but not strictly binary, and genetic testing remains the gold standard.

PFIC2 patients with BSEP deficiency also carry an increased risk of hepatocellular carcinoma and cholangiocarcinoma at a young age, which is relevant when assessing paediatric explant or resection specimens.

A plain-language guide to the molecular pathways in colorectal cancer

Colon Cancer is not one disease — it is several different diseases that all look similar under the microscope, but got there by very different routes. Understanding these routes helps explain why some bowel cancers behave differently, respond to different treatments, and arise in different patients.
There are three main roads to bowel cancer.

Road 1 — The Classical Route (the most common)
This is the familiar “polyp to cancer” story. A conventional polyp (adenoma) develops in the lining of the bowel and, over 10–15 years, accumulates a series of faults in key genes — first APC, then KRAS, then TP53. Each fault gives the cells a further growth advantage until cancer develops.
These cancers tend to be left-sided (descending colon and rectum) and are the ones most commonly detected by bowel cancer screening programmes.

Road 2 — The Serrated Route
This route starts from a different type of polyp — the sessile serrated lesion. These polyps are flat, pale, and easy to miss at colonoscopy, which is one reason this pathway is clinically important.
The first genetic fault here is in a gene called BRAF. What happens next is unusual — instead of accumulating more gene mutations, the tumour takes an epigenetic shortcut.
What does epigenetic mean?
Think of genes as light switches. A genetic mutation breaks the switch permanently. An epigenetic change is different — it puts a piece of “sticky tape” over the switch, keeping it off without actually breaking it. The gene is still physically intact but cannot be read. This chemical silencing process uses methyl groups and is called methylation.
In the serrated pathway, sticky tape is applied to the control switches of multiple genes simultaneously — a process called CIMP (CpG island methylator phenotype), or simply being “methylated”.
What happens next depends on which genes get silenced:
• If the sticky tape lands on MLH1 — the gene that proofreads and repairs DNA copying errors — the cell loses its ability to correct mistakes. Errors pile up rapidly in short repetitive DNA sequences called microsatellites. This is called microsatellite instability (MSI-H). These cancers have a very high number of mutations, attract a large immune response, tend to be right-sided, occur more often in older women, and respond very well to modern immunotherapy drugs.
• If the sticky tape does NOT silence MLH1, the cancer remains genomically stable (MSS). Paradoxically, this subgroup tends to behave more aggressively and does not respond to immunotherapy.
What about MSI-Low (MSI-L)?
You will sometimes see a third category — MSI-Low (MSI-L) — in reports and papers. This means there is a small degree of microsatellite instability, more than a fully stable tumour but nowhere near the level seen in MSI-H. In practice, MSI-L is a borderline or intermediate result. Most MSI-L tumours behave biologically more like MSS cancers than MSI-H cancers — they do not carry the same good prognosis, do not respond to immunotherapy, and are not generally associated with Lynch syndrome. MSI-L is thought to reflect minor, incidental errors in DNA copying rather than a true failure of the mismatch repair system. In most clinical algorithms, MSI-L is grouped with MSS for treatment decisions.

Road 3 — Lynch Syndrome (the inherited route)
Lynch syndrome also produces MSI-H cancers, but through a completely different mechanism. Here, a person is born with a faulty copy of one of the DNA repair genes. There is no sticky tape involved — the problem is hardwired into every cell of the body from conception.
How is it inherited?
Lynch syndrome follows an autosomal dominant pattern of inheritance. This means:
• Only one faulty copy of the gene is needed — inherited from one parent — to carry the syndrome. You do not need two faulty copies.
• Each child of an affected parent has a 50% chance of inheriting the faulty gene.
• It affects men and women equally.
• The faulty gene may have come from either the mother’s or father’s side of the family.
The genes involved are the mismatch repair genes: MLH1, MSH2, MSH6, and PMS2. Carrying a faulty copy does not guarantee cancer — it raises the lifetime risk substantially (up to 70–80% for bowel cancer with MLH1/MSH2 mutations) but is not inevitable. This is why Lynch families are offered regular surveillance colonoscopy.
Lynch syndrome also increases the risk of cancers in other organs — particularly the womb (endometrium), ovary, stomach, urinary tract, and small bowel — because the same repair machinery operates throughout the body.
The key distinction from the serrated pathway is that CIMP and BRAF mutation are absent in Lynch syndrome. Both arrive at MSI-H by different roads.

Detecting MMR Deficiency: IHC versus Molecular MSI Testing
In routine clinical practice, there are two completely different laboratory methods used to detect defective DNA repair in bowel cancers. They measure different things, and it is important not to confuse them.
Immunohistochemistry (IHC) — looking at the proteins
IHC is a staining technique performed by the pathologist on the tumour tissue section. Antibodies are applied that specifically bind to the four MMR proteins — MLH1, MSH2, MSH6, and PMS2 — and a colour reaction shows whether each protein is present or absent in the tumour cell nuclei.
In a normal tumour, all four proteins stain positively (present). If one or more proteins are lost, this indicates that the corresponding gene has been switched off or mutated — the cancer is said to show loss of MMR protein expression, or to be dMMR (deficient mismatch repair).
IHC has additional diagnostic value: the pattern of loss points towards the likely cause:
• Loss of MLH1 and PMS2 together → most likely sporadic (epigenetic silencing via CIMP, as in the serrated pathway). MLH1 methylation testing can confirm this.
• Loss of MSH2 and MSH6 together → strongly suggests Lynch syndrome (germline MSH2 mutation).
• Isolated loss of MSH6 or PMS2 → may indicate Lynch syndrome with a mutation in that specific gene.
• Loss of MLH1/PMS2 in a younger patient, or without BRAF mutation → raises suspicion for Lynch syndrome even if MLH1 is lost.
IHC is widely available, inexpensive, fast, and gives results the pathologist can interpret directly from the slide. However, it tests for protein — it tells you the protein is missing but does not directly measure what is happening to the DNA.
Molecular MSI Testing — looking at the DNA directly
Molecular MSI testing (also called PCR-based MSI testing or next-generation sequencing MSI analysis) works at the DNA level. It directly measures the lengths of specific short repetitive DNA sequences — microsatellites — in the tumour compared to normal tissue. If these sequences are abnormally variable in length, the tumour is called MSI-H. If they are stable, it is called MSS.
This test does not look at proteins at all. It confirms functionally that the DNA repair machinery has failed, regardless of which protein caused the problem or why.
So which test does what?
Think of it this way:
• IHC asks: which MMR protein is missing from the tumour? It identifies the defective component and points towards the mechanism (sporadic vs Lynch).
• Molecular MSI testing asks: has the loss of that protein actually caused DNA repair failure? It confirms the functional consequence.
• The two tests usually agree — a tumour that is dMMR by IHC is almost always MSI-H by molecular testing, and vice versa. But there are occasional discordant cases where one test is positive and the other negative, which is why both may be used in complex or equivocal situations.
• IHC is the standard first-line test in most pathology laboratories because it is practical and gives mechanistic clues. Molecular MSI testing is used to confirm, for clinical trials, or when IHC results are equivocal.
• Neither test on its own tells you whether the MMR deficiency is due to Lynch syndrome (germline, inherited) or sporadic methylation — that question requires germline genetic testing of the patient’s blood DNA, ideally guided by the IHC pattern and MLH1 methylation status.

The Bottom Line
• MSI (microsatellite instability) is the consequence — the end result of broken DNA repair, whatever the cause.
• MSI-H means the repair system has truly failed. MSI-L is a borderline finding that usually behaves like MSS and does not indicate Lynch syndrome.
• CIMP (methylation) is one mechanism that can cause MSI-H — by chemically silencing the MLH1 repair gene with sticky tape.
• The serrated pathway is the route — a distinct biological journey, starting from a different polyp, that frequently leads to CIMP and MSI-H.
• Lynch syndrome arrives at the same MSI-H destination by an entirely different, inherited road — a germline gene fault passed from parent to child with 50% probability.
• IHC and molecular MSI testing are complementary tools: IHC identifies which protein is lost and guides the search for the cause; molecular testing confirms that DNA repair has functionally failed.

Quick Reference Glossary
CIMP — CpG island methylator phenotype. The process of chemically silencing multiple genes simultaneously via methylation.
dMMR — Deficient mismatch repair. Detected by IHC as loss of one or more MMR proteins.
Epigenetic — Changes that affect gene activity without altering the DNA sequence itself.
IHC (Immunohistochemistry) — A staining technique that detects specific proteins in tissue sections using antibodies.
Methylation — Addition of methyl groups to gene promoters, acting like sticky tape over a switch to silence gene expression.
MMR — Mismatch repair. The cellular machinery that proofreads and corrects DNA copying errors.
MSI-H — Microsatellite instability-high. Confirms functional failure of DNA mismatch repair; high mutation burden; responds to immunotherapy.
MSI-L — Microsatellite instability-low. A borderline finding; behaves clinically like MSS; not associated with Lynch syndrome.
MSS — Microsatellite stable. Normal DNA repair function.
Autosomal dominant — Inheritance pattern where one faulty copy of a gene (from either parent) is sufficient to cause the condition; 50% transmission risk per child.
Lynch syndrome — An inherited condition caused by a germline mutation in an MMR gene (MLH1, MSH2, MSH6, or PMS2), predisposing to bowel and other cancers.
BRAF / KRAS / APC / TP53 — Genes that when mutated drive cancer development along different pathways.

Reference: Guinney et al., Nature Medicine 2015 (Consensus Molecular Subtypes) | WHO Classification of Digestive System Tumours

Medical Liver Biopsies for Trainees.

Acute Hepatitis

Distinguish acute and chronic hepatitis.

Liver disease lasting less (acute) or more (chronic) 6 months.

Describe the natural history of hepatitis.

Acute hepatitis > chronic hepatitis > cirrhosis

Name the 2 commonest causes of acute hepatitis.

  1. Drugs
  2. Viruses

Name 5 viruses which cause acute hepatitis.

HAV, HBV, HCV, HDV and HEV

Name one drug that causes an acute hepatitis.

Paracetamol

Describe the characteristic histological features of an acute hepatitis.

Spotty (lobular) hepatocyte necrosis and inflammation

 

Chronic Hepatitis

Name the 3 causes of a chronic hepatitis

  1. Viruses
  2. Drugs
  3. Autoimmune

Define grade with reference to chronic hepatitis.

The activity of the inflammation (portal, interface and lobular).

Define stage with reference to chronic hepatitis.

The degree of fibrosis ranging from portal tract expansion through bridging fibrosis to nodule formation (= cirrhosis).

Name the scoring system for grading and staging chronic hepatitis that you use in your hospital.

Modified HAI (Ishak) / METAVIR

 

Viral Hepatitis

Name 3 viruses which cause chronic hepatitis.

HBV, HCV and HDV (causes co-infection / superinfection with HBV).

Describe the characteristic histological feature of chronic hepatitis B.

Ground glass cells, immunopathic hepatocyte damage

Describe the 3 characteristic histological features of chronic hepatitis C.

Inflammatory bile duct damage, lymphoid follicle formation, fatty change (Genotype 3).

Describe the characteristic histological feature of hepatitis D.

Cytopathic hepatocyte damage

 

Auto-immune Hepatitis

List the main clinical features.

Younger women, often associated with other autoimmune diseases

Classify auto-immune hepatitis.

Type 1 Associated with smooth muscle actin antibodies in adults (and the commonest one we see).

Type 2 associated with liver-kidney microsomal antibodies, commoner in children

Describe the 2 characteristic histological features of auto-immune hepatitis.

Marked, especially interface, inflammation and prominent plasma cells.

Be aware of the existence of overlap syndromes.

With PBC and PSC.

 

Drug induced hepatitis  

and Drug Induced Liver Injury (DILI)

Describe the range of liver diseases that can be caused by a drug.

‘Any kind of liver disease can be caused by a drug”.

Describe 5 characteristic histological features of a drug-induced hepatitis.

Fatty change, eosinophils, granulomas, cholestasis, dropout

Name one drug which causes a chronic hepatitis.

Isoniazid

 

Fatty Liver Disease:

 

Describe the natural history of fatty liver hepatitis.

Fatty change> fatty liver hepatitis > cirrhosis

Describe the 2 morphological types of fatty change.

Small droplet (microvesicular) and large droplet (macrovesicular)

List the 2 common causes of each type of fatty change.

Small droplet: Drugs (e.g. sodium valproate) and pregnancy.

Large droplet: Alcohol and Diabetes (insulin resistance).

List 4 other causes of large droplet fatty change.

Drugs (e.g. steroids), viruses (HCV), starvation and other metabolic diseases (e.g. Wilson’s Disease).

Describe the 4 key histological features of a fatty liver hepatitis.

All changes most marked in Zone 3: ballooning (with or without Mallory-Denk bodies), inflammation (lymphocytic and / neutrophilic, pericellular fibrosis.

Know which histological feature may help distinguish alcoholic from non-alcoholic fatty change.

Nuclear vacuolation which is associated with insulin resistance.

Know the associations of nuclear vacuolation.

Physiological: childhood and young adults.

Pathological:   insulin resistance, Wilson’s Disease and glycogen storage diseases.

Name the 2 commonest causes of a fatty liver hepatitis.

Alcohol and Diabetes / insulin resistance (= Non-Alcoholic Steato-Hepatitis)

These 3 stages may co-exist

Name one drug that causes a fatty liver hepatitis.

Tamoxifen

Name the scoring system for grading and staging chronic hepatitis that you use in your hospital.

Nash Activity Score (NAS) and Stage

 

 

Primary biliary cholangitis (PBC)

List the main clinical features.

Middle aged, females

The presence of anti-mitochondrial antibodies is the key diagnostic test.

Describe the key histological feature.

Inflammatory destruction of bile ducts often associated with granulomas.

General features of chronic cholestatic liver disease (see below).

Progressive portal fibrosis but less than half are cirrhotic at presentation

 

Primary sclerosing cholangitis (PSC)

List the key clinical features.

Younger men

Associated with ulcerative colitis.

Increased risk of cholangiocarcinoma.

Imaging is the key diagnostic test,

Describe the key histological feature.

Fibrotic destruction of bile ducts.

Progressive portal fibrosis.

Involves mainly the extrahepatic bile ducts.

 

List the diseases that cause bile duct loss.

  1. PBC
  2. PSC
  3. Drug-induced liver disease e.g. ketamine
  4. Chronic liver transplant rejection
  5. Graft versus Host Disease etc.

 

Know the general features of chronic cholestatic liver disease and which special stains are needed to demonstrate them.

  1. Bile duct loss
  2. Proliferation of intermediate-type hepatocyte progenitor cells.
  3. Accumulation of copper and copper associated protein in periportal hepatocytes.
  4. Ballooning degeneration of periportal hepatocytes (with or without Mallory-Denk bodies).

1 and 2 confirmed on CK7 staining.

Copper-associated protein: metallothionine

Copper: rubeanic acid

 

List the features which assess the active damage of biliary tract disease.

  1. bile duct inflammation
  2. interface hepatitis

 

List the features which assess the chronic damage of biliary tract disease.

  1. portal fibrosis
  2. interlobular bile duct loss
  3. deposition of copper associated protein.

 

Wilson ’s disease

List the main clinical features.

Associated with neurological problems (“hepato-lenticular degeneration”) and eye involvement (Kayser-Fleisher rings).

Should always be considered in younger patients with unexplained liver disease.

Describe the underlying pathophysiology

Autosomal recessive with no dominant mutation.

Failure of copper excretion by hepatocytes into the biliary system due the failure to express a transporter protein

Describe the range of histological features.

From fatty liver hepatitis to chronic hepatitis.

Increased copper or copper associated protein can only be demonstrated, histologically, in half of cases:

The gold standard is liver copper measurement.

NB Copper also increased in chronic biliary tract diseases but not the same extent.

 

Haemochromatosis

List the main clinical features

Presents in adults but in men earlier than in women.

Describe the underlying pathophysiology

Autosomal recessive with a single dominant mutation (HFe)

Increased iron absorption from the gut. NB There is no method for excreting iron

Describe the key histological features.

Iron deposition in hepatocytes starting in the periportal hepatocytes and then spreading to the rest of the lobule.

Progressive portal fibrosis.

Be able to distinguish this from other causes of iron overload.

Chronic anaemia, also, leads to increased iron absorption from the gut and deposition in hepatocytes.

Blood transfusion leads to iron deposition in Kupffer cells and does not, usually, lead to fibrosis.

 

Alpha-1 antitrypsin deficiency

List the key clinical features

Associated with emphysema

Describe the key histological feature.

dPAS positive globules in periportal hepatocytes.

 

IgG Related Disease (IgG4)

List the main clinical features

Often part of systemic disorder

Often involves the hepato-biliary (and pancreatic) system producing, e.g.:

  1. A mass lesion in the liver
  2. A PSC like disease

List the 3 key histological features.

  1. Increased numbers of IgG4 expressing plasma cells.
  2. Storiform fibrosis
  3. Vasculo-obliterative lesions

 

Granulomas

Know a classification of granulomas in the liver:

  1. Aetiolgical
  2. Practical
  3. Where you know the cause:

e.g. see a schistosome egg or acid-fast bacilli

  1. Where you can have an educated guess:

e.g. Associated with bile duct damage (PBC) or portal based, fibrotic granuloma with little associated inflammation (Sarcoid) or associated with other features suggesting DILI.

  1. The rest!

 

Vascular Diseases of the Liver

Describe the clinical associations and key histological features of the main vascular diseases of the liver.

  1. Budd Chiari Syndrome

Thromboses of hepatic vein / branches etc.

Associated with pro-thrombotic states

Marked congestion, with extravasation of red cells onto hepatocytes, and patent central veins.

  1. Veno-occlusive disease

Fibrotic obliteration of portal vein branches.

Associated with azathioprine, radiation and Jamaican bush tea

  1. Sinusoidal obstruction syndrome.

Sinusoidal damage with congestion and haemorrhage,

Associated with chemotherapy,

  1. Primary portal hypertension.

Obliteration of hepatic vein branches and sinusoidal herniation.

  1. Nodular regenerative hyperplasia.

Regenerative nodules but no fibrosis.

Associated with systemic diseases

 

 

Cirrhosis

 

Define cirrhosis.

End stage liver disease:

  1. involving the whole liver,
  2. associated with fibrosis,
  3. nodules of regenerating hepatocytes and
  4. shunting of blood (intrahepatic and extrahepatic)

List the 3 commonest causes of cirrhosis

  1. Viral hepatitis
  2. Alcoholic liver disease
  3. Non- alcoholic fatty liver disease (NAFLD)

List 4 other causes of cirrhosis.

  1. PBC
  2. PSC
  3. DILI
  4. Hemochromatosis

Know how to classify cirrhosis.

  1. According to the aetiology
  2. According to the sizes of the nodules

Micronodular (smaller than a normal liver lobule) – alcohol

Macronodular (bigger than a normal liver lobule) – viral hepatitis

Mixed

 

List 3 complications of cirrhosis.

  1. Portal hypertension.
  2. Liver failure
  3. Liver cell cancer